Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically proven non-small cell lung cancer with at least 1 lesion accessible
for endobronchial or percutaneous injection

- Measurable or evaluable disease

- Must have a requirement for palliative radiotherapy to the thorax

- Clinically stable enough to undergo 3 adenovirus injections

PATIENT CHARACTERISTICS:

Age:

- 18 and over

Performance status:

- ECOG 0 or 1

Life expectancy:

- At least 12 weeks

Hematopoietic:

- Platelet count greater than 100,000/mm^3

Hepatic:

- PT and PTT normal

Renal:

- Not specified

Cardiovascular:

- No New York Heart Association class III or IV heart disease

Other:

- No active systemic viral, bacterial, or fungal infection requiring treatment

- No concurrent illness requiring hospitalization or IV medications or psychologic,
familial, sociologic, geographic, or other concurrent condition that would preclude
adequate follow up and compliance

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- HIV negative

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- No prior adenoviral gene therapy

- Any number of any type of other prior biologic therapy allowed

Chemotherapy:

- Any number of any type of prior chemotherapy allowed

- At least 2 weeks since prior systemic cancer therapy and no worse than grade 2
toxicity in any organ

Endocrine therapy:

- Any number of any type of prior endocrine therapy allowed

Radiotherapy:

- See Disease Characteristics

- No prior radiotherapy greater than 50 Gy if prior and concurrent radiation fields
include the spinal cord

- No prior radiotherapy in fraction sizes greater than 2 Gy with the spinal cord in the
concurrent radiation field

Surgery:

- At least 4 weeks since surgical resection of lung tissue

- At least 2 weeks since any other prior surgery requiring general anesthesia and
recovered